Rare Influenza A (H3N2) Variants with Reduced Sensitivity to Antiviral Drugs by Dapat, Clyde et al.





Clyde Dapat,1 Yasushi Suzuki,1 Reiko Saito, 
Yadanar Kyaw, Yi Yi Myint, Nay Lin, 
Htun Naing Oo, Khin Yi Oo, Ne Win, 
Makoto Naito, Go Hasegawa, Isolde C. Dapat, 
Hassan Zaraket, Tatiana Baranovich, 
Makoto Nishikawa, Takehiko Saito, 
and Hiroshi Suzuki
In 2007 and 2008 in Myanmar, we detected inﬂ  uenza 
viruses A (H3N2) that exhibited reduced sensitivity to both 
zanamivir and amantadine. These rare and naturally occur-
ring viruses harbored a novel Q136K mutation in neuramini-
dase and S31N mutation in M2. 
A
damantanes and neuraminidase inhibitors (NAIs) 
are the 2 classes of drugs indicated for preventing or 
treating inﬂ  uenza virus infection. In 2005, the high preva-
lence of inﬂ  uenza viruses A (H3N2) with S31N mutation 
in M2 limited the effectiveness of amantadine (1,2). In 
2008, the emergence of subtype H1N1 with H274Y muta-
tion in neuraminidase (NA) raised concerns about the use 
of oseltamivir (3,4). On the other hand, the incidence of 
zanamivir-resistant viruses was low (5). In 1998, 1 case of 
zanamivir-resistant inﬂ  uenza B virus, which was isolated 
from an immunocompromised child who underwent pro-
longed zanamivir treatment, was reported (6). In 2008, sub-
type H3N2 with D151A/V mutations in NA demonstrated 
reduced zanamivir sensitivity by chemiluminescent NAI 
assay (5). Recently, zanamivir-resistant subtype H1N1 iso-
lates with a novel Q136K mutation in NA were isolated in 
Oceania and Southeast Asia (7).
We report the detection of inﬂ  uenza viruses A (H3N2) 
harboring a Q136K mutation in NA and an S31N mutation 
in M2, which respectively confer reductions in zanamivir 
and amantadine susceptibility. In 2007 and 2008, we per-
formed phenotypic and genotypic analyses in characteriz-
ing these viruses from Myanmar.
The Study
Nasopharyngeal swabs were collected from patients 
with inﬂ  uenza-like illness at Sanpya Hospital in Yangon, 
Myanmar, and outpatient clinics afﬁ  liated with the Depart-
ment of Medical Research (Central Myanmar) in Nay Pyi 
Taw. Rapid test kit–positive samples were sent to Niigata 
University, Japan, for subsequent analyses. Virus isola-
tion and subtyping PCR were performed as previously de-
scribed (8). The NAI susceptibility test was performed by 
a ﬂ  uorescence-based NA activity assay that measures the 
50% inhibitory concentration (IC50) by using zanamivir and 
oseltamivir carboxylate (9). All samples were assayed in 
duplicates in >2 independent experiments. A sample was 
considered an extreme outlier if its IC50 value was 10× 
higher than the mean values for sensitive strains with >3 
interquartile range from the 25th and 75th percentiles in 
the box-and-whisker plot analysis (9). So far, all known 
NAI-resistant viruses are extreme outliers (10). Screening 
for S31N mutation in M2 was done by cycling probe real-
time PCR (11). Sequencing and phylogenetic analysis of 
the hemagglutinin (HA) and NA genes were performed as 
previously described (8).
A total of 253 and 802 rapid test kit–positive samples 
were collected in Myanmar in 2007 and 2008, respective-
ly. Of these, 64 isolates of subtype H3N2 were detected 
in 2007 and 211 in 2008. NAI susceptibility assay showed 
1 (1.5%) isolate (A/Myanmar/M187/2007) with a zanami-
vir IC50 value of 59.72 nM, which was collected in August 
2007, and 1 (0.5%) isolate (A/Myanmar/M114/2008) with 
a zanamivir IC50 of 33.37 nM, which was collected in July 
2008. These isolates respectively demonstrated a 53× and 
30× reduction in zanamivir susceptibility (Table) and were 
extreme outliers (data not shown). On the basis of cycling 
probe real-time PCR assay, these viruses had an S31N mu-
tation in M2, which confers resistance to amantadine. All 
subtype H3N2 viruses analyzed in this study remain sensi-
tive to oseltamivir carboxylate (Table).
Phylogenetic analysis of the HA and NA genes showed 
that the isolates with reduced sensitivity to zanamivir be-
longed to 2 distinct clusters (Figure 1). These viruses ac-
cumulated 2 and 3 amino acid (aa) substitutions in HA and 
6 and 2 aa changes in NA in 2007 and 2008 (Figure 1), 
respectively. Epidemiologic and sequencing data did not 
suggest any link between the cases. Analysis of the NA 
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zanamivir had a glutamine (Q) to lysine (K) substitution at 
aa position 136. Sequence chromatograms showed a het-
erogeneous population of virus possessing either Q or K 
at position 136, with a dominant peak for the K136 mutant 
(Figure 2). Direct sequencing of primary samples showed 
a similar proﬁ  le of chromatogram with a higher signal for 
the K136 mutant and a minor peak for the Q136 wild-type 
strain (Figure 2). The rest of the zanamivir-sensitive iso-
lates in 2007 and 2008 had the Q136 genotype, and no 
NAI-resistant-associated mutations were detected else-
where in the NA gene.
Conclusions
In this study, we detected a novel inﬂ  uenza virus A 
(H3N2) with Q136K mutation in NA and S31N mutation 
in M2, which demonstrated reduced susceptibility to both 
zanamivir and amantadine but remained susceptible to 
oseltamivir. These Q136K viruses were isolated at a low 
frequency (<1.5%) in Myanmar in 2007 and 2008. Phy-
logenetic analysis showed that these viruses were already 
amantadine-resistant with S31N mutation in M2. Amanta-
dine-resistant viruses with S31N mutation have been the 
predominant circulating strains among subtype H3N2 vi-
ruses in Myanmar since 2005 (8). The Q136K substitution 
in NA was probably generated by spontaneous point muta-
tion. The HA and NA gene sequences of Q136K mutants 
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Table. Characteristics of subtype H3N2 influenza viruses with Q136K mutation in NA and S31N substitution in M2* 
















All NAI-sensitive subtype 
H3N2 isolates‡ 
MDCK2 None 1.12 ± 0.40  1 0.86 ± 0.44  1 Resistant (S31N) 
A/Myanmar/M187/2007  MDCK2 Q136K 59.72 ± 3.83  53.3 0.13 ± 0.05  0.2 Resistant (S31N) 
A/Myanmar/M114/2008  MDCK2 Q136K 33.37 ± 7.02  29.8 0.16 ± 0.03  0.2 Resistant (S31N) 
A/Texas/131/2002§  None 1.43 ± 0.09  1.3 0.99 ± 0.09  1.2 Sensitive
A/Texas/131/2002_E119V§  E119V 5.43 ± 0.68  4.8 94.33 ± 2.06  109.7 Sensitive
*NA, neuraminidase;IC50, inhibitory concentration; NAI, neuraminidase inhibitors. 
†Amantadine sensitivity was based on M2 genotyping data. 
‡Average IC50 was calculated excluding the control viruses (n = 47).  
§Reference strains used as drug-sensitive and -resistant control viruses in the NAI assay. 
Figure 1. Phylogenetic analysis of the A) hemagglutinin (HA) and B) neuraminidase (NA) genes of inﬂ  uenza virus A (H3N2) isolates in 
Myanmar in 2007 and 2008. Trees were generated by using the neighbor-joining method. Bootstrap values >70% of 1,000 replicates and 
amino acid changes that characterize a branch are indicated on the left side of the node. Amantadine-resistant isolates with S31N mutation 
in M2 are marked with asterisks, and isolates with reduced sensitivity to zanamivir with Q136K mutation in NA are marked with squares. 
GenBank accession no. of the genomic sequences of isolates are GQ478849–GQ478866. Nucleotide sequences of the HA and NA genes 
of vaccine strains and isolates from other countries were obtained from the National Center for Biotechnology Information Inﬂ  uenza Virus 
Resource (www.ncbi.nlm.nih.gov/genomes/FLU). Scale bar indicates nucleotide substitutions per site. Rare Inﬂ  uenza (H3N2) Variants
were submitted to GenBank under accession nos. A/Myan-
mar/M187/2007: FJ229893 (HA), FJ229860 (NA) and 
A/Myanmar/M114/2008: GQ478854 (HA), GQ478863 
(NA).
Hurt et al. recently reported the characterization of 
zanamivir-resistant subtype H1N1 with Q136K mutation 
in NA (7). Zanamivir IC50s of these viruses ranged from 6 
nM to 238 nM (7); which differed from the 1–60 nM range 
of subtype H3N2 viruses obtained in this study. This ﬁ  nd-
ing may be due to differences in subtype and variations in 
the assay. The Q136K mutation was not detected in the pri-
mary clinical samples by sequencing (7); however, in our 
study, the Q136K mutation in subtype H3N2 isolates was 
detected in primary samples. Comparison of the sequence 
chromatograms between original samples and virus iso-
lates showed a similar proﬁ  le, suggesting that the Q136K 
mutants were present in primary samples of subtype H3N2 
isolates. The presence of Q136K variants in primary sam-
ples appears to be subtype-speciﬁ  c because these mutants 
were present in very low proportions among subtype H1N1 
viruses (12). To determine whether mutations exist in other 
gene segments associated with Q136K mutations, we per-
formed a full genome analysis of Q136K mutants and wild-
type viruses. We found no additional mutations in Q136K 
strains, which suggest that the genetic background of these 
viruses can compensate for the K136 mutation. However, 
further study is needed to conﬁ  rm whether the accumulated 
5 aa changes in HA and 8 substitutions in NA would com-
pensate for the Q136K mutation.
We searched the database for NA sequences of in-
ﬂ  uenza viruses A (H3N2) with Q136K mutation that are 
available on GenBank. Of the 3,381 sequences obtained, 
4 sequences from human inﬂ  uenza, which were isolated in 
1995, 2003, 2004, and 2007, and 1 sequence from swine 
inﬂ  uenza, which was isolated in Japan in 1997, contained 
the Q136K substitution. Sequences from Q136K mutants 
isolated before 2007 showed no mutations in the M2 gene. 
The data indicate that these viruses occur naturally because 
some of the isolates in the database were obtained before 
introduction of zanamivir into clinical practice in 1999 in 
Australia, New Zealand, United States, and Europe (9,13). 
In addition, Myanmar patients who shed these Q136K vi-
ruses did not receive any NAIs. The clinical relevance of 
Q136K mutants is unknown. Further study is needed to 
evaluate the effectiveness of zanamivir in patients infected 
with Q136K mutants.
Continued monitoring of viruses with reduced sensi-
tivity to NAI and adamantanes is needed, and routine sur-
veillance should include both phenotypic and genotypic 
assays. The Q136K substitution in NA should be used as 
a molecular marker associated with reduced NAI suscep-
tibility not only in subtype H1N1 isolates but also among 
subtype H3N2 isolates.
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Figure 2. Detection of Q136K substitution 
in neuraminidase by sequencing in 
primary samples and virus isolates. 
Arrows indicate the ﬁ   rst peak of the 
codon encoding amino acid position 
136. Comparison of the sequence 
chromatogram showed a mixed population 
of bases in both original clinical samples 
and virus isolates, with a dominant peak 
for 136K (AAG) mutants, compared with 
wild-type 136Q (CAG) viruses.References
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This genus of gram-negative bacteria was named after bacteriologist Alexandre-Émile-John Yersin (1863–1943). 
Born in Switzerland, he studied medicine in Paris and began a successful early career in the laboratory. He worked 
on rabies with Pierre Roux and on the tubercle bacillus under Robert Koch in Germany. He later worked at the 
Institut Pasteur on the toxic properties of the diphtheria bacillus and eventually signed on as a doctor on a ship 
headed for Saigon and Manila. In 1894, while he still worked for a French shipping company, he investigated an 
outbreak of plague in Hong Kong. After 7 days in a makeshift laboratory, he isolated the plague bacterium, which 
he called Pasteurella pestis.
Japanese bacteriologist Shibasaburo Kitasato had arrived in Hong Kong, a few days before Yersin and also had 
isolated the bacterium. Kitasato published his ﬁ  ndings in English and Japanese. Yersin published his in French. 
He also established a laboratory in Nha Trang, Vietnam, where he developed an antiplague serum that reduced the 
death rate from 90% to ≈7%. Since 1970, the organism has been called Yersinia pestis.
Source:  Burns W. Alexandre Yersin and his adventures in Vietnam. 2003; Medical Research Council National Institute for 
Medical Research. http://www.himr.mrc.ac.uk/millhillessays/2003/yersin/; http://www.whonamedit.com/doctor.cfm/2454.html; 
Dorland’s illustrated medical dictionary, 31st ed. Philadelphia: Saunders Elsevier; 2007. 